Other languages Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
0.5609 ^USD	-1.28%		-10.11%	+9.38%

May. 20	Sector Update: Health Care Stocks Ease Monday Afternoon	MT
May. 20	Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting	May. 29
Sector Update: Health Care Stocks Ease Monday Afternoon	May. 20
Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise	May. 20
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA	May. 20
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA	May. 20
Atara Biotherapeutics: Q1 Earnings Snapshot	May. 09
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q1 Revenue $27.4M	May. 09
Atara Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress	May. 09
ATARA BIOTHERAPEUTICS, INC. REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)	May. 06
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	May. 03
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating	Apr. 01
Eric Dobmeier Not to Stand for Re-Election as Member of Board of Directors of Atara Biotherapeutics, Inc	Mar. 29
Atara Biotherapeutics: Q4 Earnings Snapshot	Mar. 28
Atara Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress	Mar. 28
Earnings Flash (ATRA) ATARA BIOTHERAPEUTICS Reports Q4 Revenue $4.3M	Mar. 28
Atara Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 28
North American Morning Briefing : Stocks Edge -2-	Mar. 27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Atara Biotherapeutics, Inc.

Equities

ATRA

US0465131078

Other languages

Filters